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The Fragile Histidine Triad gene, encompassing the FRA3B fragile site at chromosome 3p14.2, is a candidate tumour suppressor
gene involved in multiple tumour types including colorectal carcinomas. Recently, it has been reported that the Fragile Histidine
Triad gene may be a target of damage in a fraction of mismatch deﬁcient tumours. To explore this hypothesis, we analysed
both Fragile histidine triad and mismatch repair protein (Msh2 and Mlh1) expression using immumohistochemical methods in
52 advanced colorectal carcinomas (19 well-, 17 moderately-, and 16 poorly-differentiated). In addition, we examined whether
the Fragile histidine triad and mismatch repair protein expression correlated with p53 expression and clinicopathological
ﬁndings. Signiﬁcant loss or reduction of Fragile histidine triad expression was noted in 18 of the 52 (34.6%) advanced
colorectal carcinomas: 2 (10.5%) well-differentiated, 3 (17.6%) moderately-differentiated, 13 (81.3%) poorly-differentiated
carcinomas, the frequency being signiﬁcantly higher in the latter than that in the former two (P50.0001). Loss of mismatch
repair protein (mainly, Mlh1) expression was detected in 21 of the 52 (40.4%) colorectal carcinomas. Moreover, reduced
Fragile histidine triad expression was signiﬁcantly associated with absence of mismatch repair protein expression in the
advanced colorectal carcinomas (P50.0001). However, the Fragile histidine triad and mismatch repair protein expression was
not signiﬁcantly associated with p53 expression. These results suggested that reduced Fragile histidine triad expression might
be correlated with mismatch repair expression, but not with p53 expression.
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A candidate tumour suppressor gene, Fragile Histidine Triad
(FHIT), was identiﬁed at chromosome 3p14.2 spanning the FRA3B
common fragile site (Ohta et al, 1996). The FHIT gene consists of
10 exons, which distribute over a genomic region of 41 Mb. The
Fragile histidine triad (Fhit) protein has been characterised as an
Ap3A hydrolase molecule, which cleaves the Ap4A substrate that
may be involved in the control of DNA replication and the cell
cycle (Ohta et al, 1996). Frequent abnormal transcripts were found
in a variety of human cancers including those of the digestive tract,
lung, breast, and head and neck (Ohta et al, 1996; Croce et al,
1999; Kitamura et al, 2001). The majority of these abnormalities
include aberrant mRNA transcripts, with the absence of one or
more exons within the mRNA. Genomic analysis demonstrated
frequent allelic loss and homozygous deletions (Ohta et al, 1996;
Croce et al, 1999).
In CRCs, Ohta et al (1996) reported that aberrant transcripts of
the FHIT gene were detected in three of eight tumours by nested
RT–PCR. In contrast, Thiagalingam et al (1996) reported that
aberrant transcripts were rare using RT–PCR, suggesting that
FHIT is inactivated by an unusual mechanism or that it plays a
role in relatively few colorectal tumours. Other reports suggested
that Fhit does indeed play a role in the development and progres-
sion of colorectal carcinomas (CRCs) (Hibi et al, 1997; Hao et al,
2000; Luceri et al, 2000; Mori et al, 2001).
Defects in the DNA mismatch repair (MMR) system are
involved in the carcinogenesis and tumour progression of sporadic
and inherited human cancers (Eshleman et al, 1996; Kinzler and
Vogelstein, 1996). MMR deﬁciency leads to the accumulation of
base-base mismatches and short insertion/deletion mispairs, gener-
ated as a consequence of DNA replication errors and homologous
recombinations. Inherited mutations of the MLH1 and MSH2
genes have been demonstrated as the cause of more than 90% of
hereditary non-polyposis colorectal cancers (HNPCC) (Peltomaki
and Vasen, 1997). MMR genes are also involved in the develop-
ment of a subset of sporadic colorectal, gastric and endometrial
tumours (Duggan et al, 1994; Halling et al, 1999; Ward et al,
2001). MMR deﬁciency, identiﬁed by the presence of microsatellite
instability (MSI), occurs in approximately 10–15% of sporadic
CRCs (Kinzler and Vogelstein, 1996). Most sporadic CRCs with
MSI have been demonstrated to be caused by somatic hypermethy-
lation of the MLH1 promoter region, resulting in the down-
regulation of MLH1 gene expression (Herman et al, 1998). Recent
data have revealed that immunohistochemistry is an accurate
screening technique to identify MMR deﬁcient tumours (Thibo-
deau et al, 1996; Marcus et al, 1999).
Recently, Fong et al (2000) have demonstrated that NMBA (N-
nitrosomethylbenzylamine) exposure caused a spectrum of visceral
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www.bjcancer.comand skin tumours similar to Muir-Torre syndrome, caused by a
deﬁciency in a MMR gene, in Fhit-deﬁcient mice, and suggested
that the FHIT gene may be a target of damage in a fraction of
mismatch deﬁcient tumours. Moreover, Mori et al (2001) reported
that the loss of Msh2 protein is signiﬁcantly correlated with the
loss of Fhit expression in human CRCs. However, the relationship
between Fhit and the MMR gene (both Msh2 and Mlh1) expres-
sion has not been previously studied in detail using clinical
samples.
In this study, we examined the immunohistochemical expression
of Fhit, Msh2, Mlh1, and p53 in advanced CRCs to explore the
hypothesis that the Fhit inactivation is a frequent result of MMR
deﬁciency.
MATERIALS AND METHODS
Patient samples
Tumour blocks were obtained from 52 patients, who underwent
colorectomy at Tottori University Hospital between 1992 and
1996. Patients with familial adenomatous polyposis (FAP) were
excluded, but family history was not an exclusion criterion; there-
fore, some cases of HNPCC may have been included in the study
population. The ages of the 27 male and 25 female patients ranged
from 51 to 90 years (mean+SD: 67.4+1.32 years). Pathologically,
all of the tumours were advanced adenocarcinomas (19 well-differ-
entiated, 17 moderately-differentiated, and 16 poorly-
differentiated). Nineteen cases had right sided tumours and 33
cases had left sided tumours. Right-sided lesions were deﬁned as
those conﬁned to the coecum or ascending or transverse colon,
whereas left-sided lesions were deﬁned as being conﬁned to the
descending colon, sigmoid colon, or rectum. On the basis of
Dukes’ classiﬁcation, four were in stage A, 12 in stage B, 21 in stage
C, and 15 in stage D. Lymph node metastases were present in 34 of
the 52 (59.6%) patients. Histological classiﬁcation was made
according to the criteria of the Colorectal Cancer Study Group
of Japan (Colorectal Cancer Study Group of Japan, 1998). All diag-
noses of pathological specimens were veriﬁed by two experienced
pathologists (H.A. and H.I.). All the cases were analysed anon-
ymously, i.e., all the specimens were given new numbers without
names. Institutional Review Board approval was obtained.
Immunohistochemical staining
Parafﬁn-embedded, 4 mm-thick sections were immunohistochemi-
cally stained with anti-FHIT rabbit polyclonal antibody (IBL,
Gunma, Japan; dilution 1:100), anti-MSH2 mouse monoclonal
antibody (FE11, Oncogene Research Products, Cambridge, MA,
USA); dilution 1:100), anti-MLH1 mouse monoclonal antibody
(G168-15, PharMingen, San Diego, CA, USA; dilution 1:50), and
anti-p53 mouse monoclonal antibody (DO-7, Dakopatts, Copenha-
gen, Denmark; dilution 1:50) using the avidin-biotin-peroxidase
complex technique. Immunohistochemical staining was performed
as described below. In brief, after deparafﬁnising in xylene and
dehydrating in ethanol, the sections were immersed in a citrate
buffer (0.01 M, pH 6.0) and heated in a microwave oven for
15 min to retrieve antigens, then incubated with the primary anti-
body overnight at 48C. As a negative control, the primary antibody
was replaced with normal serum IgG in a similar dilution. The
detection reaction followed the Vectastain Elite ABC kit protocol
(Vector Laboratories, Burlingame, CA, USA). Diaminobenzidine
was used as a chromogen, and methylgreen or haematoxylin was
used as a counterstain. The sections were then incubated with
biotinylated anti-rabbit IgG and avidin-biotin-peroxidase and
visualised using diaminobenzidine tetrahydrochloride. The immu-
nohistochemical expressions were evaluated by two independent
observers (H.A. and K.Y.). Immunohistochemical analysis was
performed in a blinded manner with respect to the clinical infor-
mation.
Assessment of Fhit immunostaining
The Fhit expression was graded for both the extent and the intensity
of immunopositivity as described previously Hao et al (2000). The
extent of positivity was scored as follows: 0, 55%; 1, 45–25%; 3,
450–75%; and 4, 475% of the colonic epithelial cells in the respec-
tive lesions. The intensity was scored as follows: 0, negative; 1+, weak;
2+, moderate; and 3+, as strong as normal mucosa. The ﬁnal score
was obtained by multiplying the extent of positivity and intensity
scores, producing a range from 0 to 12. Scores 9–12 were deﬁned
as preserved or strong staining pattern, scores 0–4 were deﬁned as
markedly reduced or lost expression, and scores 5–8 were deﬁned
as intermediate staining pattern.
Assessment of Msh2 and Mlh1 immunostaining
Normal tissue adjacent to the tumour was used as an internal posi-
tive control. The normal staining pattern for both hMlh1 and
hMsh2 was nuclear. Tumour cells that exhibited an absence of
nuclear staining in the presence of non-neoplastic cells with nucle-
ar staining were considered to have an abnormal pattern.
Assessment of p53 immunostaining
Five representative ﬁelds were examined, and a total of 1000
tumour cells (200 for each ﬁeld) were counted under the micro-
scope with a high power (6200) objective. A distinct nuclear
immunoreaction was assessed as positive. In this study, the speci-
mens were regarded as p53-positive when over 25% of the
tumour cells showed positive signals.
Statistical evaluation
Statistical analysis was performed by the Fisher’s exact test. P50.05
was considered signiﬁcant.
RESULTS
Fhit expression in the normal mucosa and advanced
cancers
By immunohistochemical staining, all the normal colonic epithelia
showed strong cytoplasmic expression of the Fhit protein from the
basal cells to the luminal differentiated cells (Figure 1A); these
served as internal controls. Smooth muscle cells and inﬂammatory
mononuclear cells were positive at various intensities and to
various degrees.
Reduced or absent Fhit expression was noted in 18 of the 52
(34.6%) advanced CRC cases, preserved in 25 (48.1%) CRCs and
intermediate in nine (17.3%) CRCs (Table 1, Figure 1A,B). The
intensity of the staining of the colorectal carcinoma cells was deter-
mined by comparing it to that of the normal colonic epithelial cells
found within the same specimen (Figure 1A).
We analysed the relationship between these results and the clin-
icopathological data (tumour location, histological differentiation,
Dukes’ stage, lymph node metastasis, and p53 expression).
Decreased staining or lack of staining for Fhit was detected in 2
of 19 (10.5%) well-differentiated cancers, in three of 17 (17.6%)
moderately-differentiated cancers, and in the 13 of 16 (81.3%)
poorly-differentiated cancers. The incidence of reduced Fhit expres-
sion in CRCs was signiﬁcantly highest in the poorly-differentiated
histology (P50.0001; Table 1). However, no signiﬁcant associa-
tions were found among the Fhit expression and other
clinicopathological parameters.
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The expression of both Mlh1 and Msh2 proteins was without
exception nuclear. In the normal mucosa, they were detected
predominantly in the areas of active proliferation, such as the germ-
inal centres of the lymphoid follicles and the lower portions of the
normal colonic crypts (Figure 2A,C). Normal stromal cells such as
ﬁbroblasts and endothelial cells also showed nuclear positivity for
both the proteins. We demonstrated that 19 of the 52 (36.5%)
tumours had reduced expression levels of the Mlh1 protein (Figure
2B), whereas ﬁve (9.6%) carcinomas had reduced expression levels
of the Msh2 protein (Figure 2D). Reduced expression levels of both
proteins were observed in three of the 52 (5.8%) specimens (Table
2). In addition, loss of nuclear Mlh1 or Msh2 expression was more
frequently associated with poor differentiation (P=0.0128) and
right-sided location (P=0.0184) (Table 1). However, there was no
signiﬁcant difference in other clinicopathological parameters (age,
gender, Dukes stage, node metastasis, and p53 expression). Among
the tumours with reduced or absent Fhit expression, 72.2% (14 of
18) had loss of nuclear Mlh1 or Msh2 expression compared with
only 20.6% (seven of 34) of the preserved or intermediate Fhit
expression tumours (P50.0001) (Table 2).
DISCUSSION
Alterations and abnormal transcripts of the FHIT gene have been
reported in a number of primary human tumours, including CRCs
(Ohta et al, 1996; Croce et al, 1999; Kitamura et al, 2001).
However, some of the data are conﬂicting in CRCs (Hao et al,
2000; Hibi et al, 1997; Luceri et al, 2000; Mori et al, 2001; Thiaga-
lingam et al, 1996). Recently, it was reported that alterations in the
FHIT locus detected by DNA and/or reverse transcription-PCR
analysis correlated with a loss of Fhit protein expression in lung,
cervical, and oesophageal carcinomas (Birrer et al, 1999; Mori et
al, 2000; Sozzi et al, 1998). These results indicated that FHIT gene
alteration can be simply detected by immunohistochemical analysis
of tumour specimens. In this study, we observed frequent abnor-
mal Fhit protein expression in poorly-differentiated CRCs, with
77% of the specimens demonstrating a decrease in, or lack of, Fhit
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Table 1 Relationship between Fhit and MMR protein expression and clinicopathological ﬁndings in advanced colorectal car-
cinoma
Fhit protein expression
M1h1/Msh2
expression
n
preserved/
intermediate
reduced or
absent P + 7 P
Histological type
well 19 17 2 13 6
moderately 17 14 3 50.0001 13 4 0.0128
poorly 16 3 13 5 11
Tumour localization
right side 19 11 8 NS 7 12 0.0184
left side 33 23 10 24 9
Dukes’ stage
A 4 4 0 NS 3 1 NS
B1 2 8 4 6 6
C2 1 1 0 1 1 1 0 1 1
D 15 12 3 12 3
Lymph node metastasis
+3 4 2 0 1 4 N S 2 0 1 4 N S
7 18 14 4 11 7
p53 expression
+3 5 2 4 1 1 N S 2 2 1 3 N S
7 17 10 7 9 8
Right-sided lesions were deﬁned as those proximal to the splenic ﬂexure. NS: not signiﬁcant.
A
B
Figure 1 Representative results of Fhit immunostaining in human normal
and carcinomatous colorectal tissues. (A), Reduced immunostaining of a tu-
mour and positive immunostaining of normal colonic epithelium; (B), Posi-
tive immunostaining of an invasive tumour
Fhit and MMR in colorectal carcinomas
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similar to that observed in poorly-differentiated CRCs by Hao et
al (2000). Therefore, these results suggest that abnormal Fhit
expression is associated with decreasing degrees of differentiation
in CRCs. However, we found no correlation between the Fhit
expression and any of the clincopathological parameters including
p53 expression.
Inactivation of MMR genes is a recently described alternate
pathway in cancer development and progression (Eshleman and
Makowitz, 1996; Kinzler and Vogelstein, 1996). MMR deﬁciency
is present in 10–15% of sporadic CRCs (Kinzler and Vogelstein,
1996), and is the underlying cause of more than 90% of HNPCC
(Peltomaki and Vasen, 1997). Previous studies demonstrated that
immunohistochemical analysis of the expression of Mlh1 and
Msh2 could be an accurate and rapid screening procedure for
the identiﬁcation of MMR gene alterations (Thibodeau et al,
1996; Marcus et al, 1999). We found abnormal Mlh1 or Msh2
expression in 21 of the 52 (46%) CRCs using immunohistochem-
ical methods. This frequency of abnormal MMR protein
expression was more frequent than that observed in CRC by other
investigators (Kinzler and Vogelstein, 1996). In the assessment of
MMR protein expression, we used almost the same criteria used
by other groups (Marcus et al, 1999; Ward et al, 2001). In addi-
tion, it was reported that sporadic CRCs with MSI were more
frequent in the poorly differentiated phenotype (Ward et al,
2001). In our study, the ratio of poorly differentiated CRCs was
high compared with previous reports (Kinzler and Vogelstein,
1996; Marcus et al, 1999; Ward et al, 2001). Therefore, high
frequency of abnormal MMR protein expression might be mainly
due to the different distributions of histological differentiation.
Moreover, we found a signiﬁcant correlation between the MMR
protein expression and histological differentiation and tumour
location. These results were also consistent with previous reports
(Kinzler and Vogelstein, 1996). In the present study, MMR deﬁ-
ciency was mainly due to the loss of Mlh1 expression,
suggesting that MLH1 hypermethylation is the predominant
mechanism (Herman et al, 1998).
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A
B
C
D
Figure 2 Representative results of Mlh1 and Msh2 immunostaining in human normal and carcinomatous colorectal tissues. A and B, Poorly-differentiated
carcinoma cells (B) show no nuclear staining for Mlh1 while normal crypt epithelium (A) shows nuclear staining; (C) Normal crypt epithlium shows nuclear
staining for Msh2; (D), Moderately-differentiated carcinoma cells show nuclear staining for Msh2
Table 2 Relationship between Fhit and MMR protein expression in
colorectal carcinoma
Fhit expression
Preserved/ Reduced
n intermediate or absent
M1h1 (+), Msh2 (+) 31 27 4
M1h1 (7), Msh2 (+) 16 4 12
M1h1 (+), Msh2 (7)2 1 1
M1h1 (7), Msh2 (7)3 2 1
Reduced Fhit expression is associated with loss of MMR expression: P50.0001.
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somethylbenzylamine) exposure, Fhit-deﬁcient mice developed a
spectrum of visceral and skin tumours similar to Muir-Torre
syndrome, caused by a deﬁciency in a MMR gene (Fong et al,
2000). A large subgroup of MTS cases exhibits MSI and germline
mutations in the MLH1 or MSH2 gene (Kruse et al, 1998). In
addition, it was previously observed that human pancreatic
cancers and cell lines with high MSI frequently had homozygous
deletions within FHIT (Hilgers and Kern, 1999; Hilgers et al,
2000). Therefore, these reports suggested that the FHIT gene
might be a target of damage in a fraction of mismatch deﬁcient
tumours. Our data show that MMR deﬁciency based on the status
of the Mlh1 and Mlh2 protein expression is signiﬁcantly asso-
ciated with reduced Fhit expression in advanced colorectal
carcinomas and support this hypothesis. Mori et al (2001)
reported an association between Msh2 absence and FHIT altera-
tions in CRCs but did not analyse Mlh1 expression. Moreover,
as the mechanisms of this hypothesis, they proposed that the
repetitive elements, such as (CA)n and (A)n repeats, in introns
4 and 5 of the FHIT gene could be a target of damage in
MMR deﬁcient tumours.
Thus, we noted an association between Fhit and MMR protein
expression, but it could be due to the result of an association between
Fhit and MMR protein expression and poorly differentiation.
In conclusion, we have demonstrated that reduced Fhit expres-
sion was associated with the loss of MMR protein expression in
advanced CRCs. In combination with previous reports, this result
supports the possibility that FHIT gene alterations could be caused
by a deﬁciency in a MMR gene. Studies that look into the regula-
tion of Fhit and MMR protein expression in cancer may offer a
new insight into colorectal carcinogenesis and plausibly, chemopre-
ventive pathways.
REFERENCES
Birrer MJ, Hendricks D, Farley J, Sundborg MJ, Bonome T, Walts MJ,
Geradts J (1999) Abnormal Fhit expression in malignant and premalignant
lesions of the cervix. Cancer Res 59: 5270–5274
Croce CM, Sozzi G, Huebner K (1999) Role of Fhit in human cancer. J Clin
Oncol 17: 1618–1624
Duggan BD, Felix JC, Muderspach LI, Tourgeman D, Zheng J, Shibata D
(1994) Microsatellite instability in sporadic endometrial carcinoma. J Natl
Cancer Inst 86: 1216–1221
Eshleman JR, Makowitz SD (1996) Mismatch repair defects in human carci-
nogenesis. Hum Mol Genet 5: 1489–1494
Fong LYY, Fidanza V, Zanesi N, Lock LF, Siracusa LD, Mancini R, Siprashvili
Z, Ottey M, Martin SE, Druck T, McCue PA, Croce CM, Heubner K
(2000) Muir-Torre-like syndrome in Fhit-deﬁcient mice. Proc Natl Acad
Sci USA 97: 4742–4747
Halling KC, Harper J, Moskaluk CA, Thibodeau SN, Petroni GR, Yustein AS,
Tosi P, Minacci C, Roviello F, Piva P, Hamilton SR, Jackson CE, Powell
SM (1999) Origin of microsatellite instability in gastric cancer. Am J Pathol
155: 205–211
Hao XP, Willis JE, Pretlow TG, Rao JS, MacLnnan GT, Talbot IC, Pretlow TP
(2000) Loss of fragile histidine triad expression in colorectal carcinomas
and premalignant lesions. Cancer Res 60: 18–21
Herman JG, Umar A, Polyak K, Graft JR, Ahuja N, Issa JPJ, Markowitz S,
Wilson JKV, Hamilton SR, Kinzler KW, Kane MF, Kolodner RD, Vogel-
stein B, Kunkel TA, Baylin SB (1998) Incidence and functional
consequences of hMLH1 promoter hypermethylation in colorectal carci-
noma. Proc Natl Acad Sci USA 95: 6870–6875
Hibi K, Taguchi M, Nakamura H, Hirai A, Fujikake Y, Matsui T, Kasai Y,
Akiyama S, Ito K, Takagi H (1997) Altenative splicing of the FHIT gene
in colorectal cancers. Jpn J Cancer Res 88: 385–388
Hilgers W, Kern SE (1999) Molecular genetic basis of pancreatic adenocarci-
noma. Genes Chromosomes Cancer 26: 1–12
Hilgers W, Koerkamp BG, Geradts J, Tang DJ, Yeo CJ, Hruban RH, Kern SE
(2000) Genomic FHIT analysis in RER+ and RER- adenocarcinomas of the
pancreas. Genes Chromosomes Cancer 27: 239–243
Colorectal Cancer Study Group of Japan (1998) The general rules for the
clinical and pathological study of primary colorectal cancer, ed 6 Tokyo:
Kinbara
Kinzler KW, Vogelstein B (1996) Lessons from hereditary colorectal cancer.
Cell 87: 159–170
K i t a m u r aA ,Y a s h i m aK ,O k a m o t oE ,A n d a c h iH ,H o s o d aA ,K i s h i m o t o
Y, Shiota G, Ito H, Kaibara N, Kawasaki H (2001) Reduced Fhit
expression occurs in the early stage of esophageal tumorigenesis:
no correlation with p53 expression and apoptosis. Oncology 61:
205–211
Kruse R, Rutten A, Lamberti C, Hosseiny-Malayeri HR, Wang Y, Ruelfs C,
Jungck M, Mathiak M, Ruzicka T, Hartschuh W, Bisceglia M, Friedl W,
Propping P (1998) Muir-Torre phenotype has a frequency of DNA
mismatch-repair- gene mutations similar to that in hereditary nonpolypo-
sis colorectal cancer families deﬁned by the Amsterdam criteria. Am J Hum
Genet 63: 63–70
Luceri C, Guglielmi F, De Filippo C, Canderni G, Mini E, Biggeri A, Napoli C,
Tonelli F, Cianchi F, Dolara P (2000) Clinicopathologic features and FHIT
gene expression in sporadic colorectal adenocarcinomas. Scand J Gastroen-
terol 35: 637–641
Marcus VA, Madlensky L, Gryfe R, Kim H, So K, Millar A, Temple LKF,
Hsieh E, Hiruki T, Narod S, Bapat BV, Gallinger S, Redston M (1999)
Immunohistochemistry for hMLH1 and hMSH2: a practical test for
DNA mismatch repair-deﬁcient tumors. Am J Surg Pathol 23: 1248–1255
Mori M, Mimori K, Shiraishi T, Alder H, Inoue H, Tanaka Y, Sugimachi K,
Huebner K, Croce CM (2000) Altered expression of Fhit in carcinoma and
precarcinomatous lesions of the esophagus. Cancer Res 60: 1177–1182
Mori M, Mimori K, Masuda T, Yoshinaga K, Yamashita K, Matsuyama A,
Inoue H (2001) Absence of Msh2 protein expression is associated with
alteration in the FHIT locus and Fhit expression in colorectal carcinoma.
Cancer Res 61: 7379–7382
Ohta M, Inoue H, Cotticelli MG, Kastury K, Baffa R, Palazzo J, Siprashvili Z,
Mori M, Macue P, Druck T, Croce CM, Huebner K (1996) The FHIT gene,
spanning the chromosome 3p14.2 fragile site and renal carcinoma-asso-
ciated t (3;8) breakpoint, is abnormal in digestive tract cancers. Cell 84:
587–597
Peltomaki P, Vasen HF (1997) Mutations predisposing to hereditary nonpo-
lyposis colorectal cancer: database and results of a collaborative study. The
International Collaborative Group on Hereditary Nonpolyposis Colorectal
Cancer. Gastroenterology 113: 1146–1158
Sozzi G, Pastorino U, Moiraghi L, Tagliabue E, Pezzella F, Ghirelli C, Torniel-
li S, Sard L, Huebner K, Pierotti MA, Croce CM, Pilotti S (1998) Loss of
Fhit function in lung cancer and preinvasive bronchial lesion. Cancer Res
58: 5032–5037
Thiagalingam S, Lisitsyn NA, Hamaguchi M, Wigler MH, Willson JKV,
Markowitz SD, Leach FS, Kinzler KW, Vogelstein B (1996) Evaluation of
the FHIT gene in colorectal cancers. Cancer Res 56: 2936–2939
Thibodeau SN, French AJ, Roche PC, Cunningham JM, Tester DJ, Lindor
NM, Moslein G, Baker SM, Liskay RM, Burgart LJ, Honchel R, Halling
KC (1996) Altered expression of hMSH2 and hMLH1 in tumors with
microsatellite instability and genetic alterations in mismatch repair gene.
Cancer Res 56: 4836–4840
Ward R, Meagher A, Tomlinson I, O’Connor T, Norrie M, Wu R, Hawkins N
(2001) Microsatellite instability and the clinicopathological features of
sporadic colorectal cancer. Gut 48: 821–829
G
e
n
e
t
i
c
s
a
n
d
G
e
n
o
m
i
c
s
Fhit and MMR in colorectal carcinomas
H Andachi et al
445
ã 2002 Cancer Research UK British Journal of Cancer (2002) 87(4), 441–445